Short description
Invectys Therapeutics is a biopharmaceutical company focused on the development of immunotherapy approaches to treat cancer.
Description
Invectys is a biopharmaceutical company focused on the development of innovative immunotherapy approaches to treat cancers. It was founded in 2010 by Pierre Langlade Demoyen and Simon Wayne-Hobson and is based in Paris.
Invectys develops a novel approach to mobilizing and restoring the anti-tumor capacity of the immune system of cancer patients. This allows virtually all cancers to be targeted. Invectys focuses its efforts on two highly prevalent tumor antigens: the nearly-universal tumor antigen telomerase that is critical to uncontrolled cell growth, and the HLA-G immune checkpoint expressed in over 50% of cancers.
Last funding
Noway Youcantaccess
Sign in for full access
Total funding
$$121212
Sign in for full access
Location
Houston, Texas, United States, North America
Founded on
January 1, 2010
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$1230 - 4560
Sign in for full access
Investors
Noaccess
Sign in for full access
Founders
Pierre Langlade, Simon Wain-Hobson